← Leaderboards
Robert P Doyle
Syracuse University
$3,168,104
Attributed
$7,796,650
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,796,650 · 5
By mechanism
R01$7,044,124 · 3
R21$531,174 · 1
R15$221,352 · 1
Top collaborators
- Bart C De Jonghe8 shared
- Matthew R Hayes8 shared
- Christian Ludwig Roth4 shared
Others in their field
Top investigators on “Obesity”
- Chanza Baytop · Westat, Inc.$271,217,917
- Judith S. Currier · University Of California Los Angeles$139,907,800
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$108,827,660
- Peter Gordon Gillespie · Oregon Health And Science University$104,808,120
- Joseph E Robertson · Oregon Health & Science University$93,739,249
Research focus
ObesityBody Weight DecreasedIn VitroMediatingPublishingNauseaShrewsGenerationsTissuesRattusVomitingAnalogMalaiseBindingBody WeightChronicDiabetes MellitusPharmacodynamicsBrain StemDrug KineticsFamilyEatingAreaObesity Treatment
Grant awards (13)
Development of Anorexigenic and Glucoregulatory Chimeric Peptides$674,227
R01 · FY2025 · DK
Development of Anorexigenic and Glucoregulatory Chimeric Peptides$644,494
R01 · FY2024 · DK
Targeting the GDF15-GFRAL system to treat nausea and emesis$643,266
R01 · FY2024 · DK
Second generation GLP-1 agonists without nausea/emesis side effects$569,065
R01 · FY2024 · DK
Efficacy of Novel Melanocortin and Gut-peptide Dual Agonists for Childhood Obesity Treatment$531,174
R21 · FY2024 · HD
Development of Anorexigenic and Glucoregulatory Chimeric Peptides$680,023
R01 · FY2023 · DK
Targeting the GDF15-GFRAL system to treat nausea and emesis$670,069
R01 · FY2023 · DK
Second generation GLP-1 agonists without nausea/emesis side effects$592,778
R01 · FY2023 · DK
Targeting the GDF15-GFRAL system to treat nausea and emesis$670,069
R01 · FY2022 · DK
Second generation GLP-1 agonists without nausea/emesis side effects$592,778
R01 · FY2022 · DK
Targeting the GDF15-GFRAL system to treat nausea and emesis$683,819
R01 · FY2021 · DK
Second generation GLP-1 agonists without nausea/emesis side effects$623,536
R01 · FY2021 · DK
Testing Oral Delivery of the Appetite Suppressing Peptide PYY3-36 Through the Vit$221,352
R15 · FY2013 · DK · contact PI